COSCIENS Biopharma Profit Margin

The latest profit margin for CSCI is -57.58% as of June 2026. That compares with -201.85% in the prior-year period — up 71.5% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside COSCIENS Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CSCI's profit margin moved from -201.85% to -57.58% — a 71.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in COSCIENS Biopharma's valuation or profitability profile.

Against Healthcare companies, CSCI currently prints -57.58% for profit margin, while the sector average sits near 21.34%. That is roughly 369.9% below the sector mean. Large gaps often invite a closer look at COSCIENS Biopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively COSCIENS Biopharma converts resources into returns. At -57.58%, CSCI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -201.85% in the prior-year period — up 71.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CSCI's profit margin (-57.58%), review year-over-year change from -201.85%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.